ACE2 and infection: The results from the current study did not find an association between the methylation levels at different CpG sites of ACE2 promoter and the development of post-COVID pain symptomatology in the one-and-a-half years after suffering from COVID-19 in a cohort of individuals who needed hospitalization due to the infection.